211 related articles for article (PubMed ID: 25090458)
21. High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug.
Skogh E; Sjödin I; Josefsson M; Dahl ML
J Clin Psychopharmacol; 2011 Feb; 31(1):4-9. PubMed ID: 21192135
[TBL] [Abstract][Full Text] [Related]
22. Impact of CYP1A2, CYP2C19, and CYP2D6 genotype- and phenoconversion-predicted enzyme activity on clozapine exposure and symptom severity.
Lesche D; Mostafa S; Everall I; Pantelis C; Bousman CA
Pharmacogenomics J; 2020 Apr; 20(2):192-201. PubMed ID: 31616047
[TBL] [Abstract][Full Text] [Related]
23. Association of the genetic polymorphisms of metabolizing enzymes, transporters, target receptors and their interactions with treatment response to olanzapine in chinese han schizophrenia patients.
Yan P; Song M; Gao B; Wang S; Wang S; Li J; Fang H; Wang C; Shi J
Psychiatry Res; 2020 Nov; 293():113470. PubMed ID: 32992097
[TBL] [Abstract][Full Text] [Related]
24. Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia.
Perera V; Gross AS; Polasek TM; Qin Y; Rao G; Forrest A; Xu J; McLachlan AJ
Expert Opin Drug Metab Toxicol; 2013 Sep; 9(9):1115-37. PubMed ID: 23641727
[TBL] [Abstract][Full Text] [Related]
25. Influence of CYP1A1/CYP1A2 and AHR polymorphisms on systemic olanzapine exposure.
Söderberg MM; Haslemo T; Molden E; Dahl ML
Pharmacogenet Genomics; 2013 May; 23(5):279-85. PubMed ID: 23492908
[TBL] [Abstract][Full Text] [Related]
26. Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism.
Sachse C; Bhambra U; Smith G; Lightfoot TJ; Barrett JH; Scollay J; Garner RC; Boobis AR; Wolf CR; Gooderham NJ;
Br J Clin Pharmacol; 2003 Jan; 55(1):68-76. PubMed ID: 12534642
[TBL] [Abstract][Full Text] [Related]
27. Cytochrome P450 1A2 co-determines neuroleptic load and may diminish tardive dyskinesia by increased inducibility.
Ivanova SA; Toshchakova VA; Filipenko ML; Fedorenko OY; Boyarko EG; Boiko AS; Semke AV; Bokhan NA; Aftanas LI; Loonen AJ
World J Biol Psychiatry; 2015 Apr; 16(3):200-5. PubMed ID: 25602162
[TBL] [Abstract][Full Text] [Related]
28. Exploring clozapine pharmacokinetics in Tunisian schizophrenic patients: A population-based modelling approach investigating the impact of genetic and non-genetic variables.
Mansour K; Fredj NB; Ammar H; Romdhane HB; Mhalla A; Chaabane A; Chadli Z; Aouam K
Basic Clin Pharmacol Toxicol; 2024 Jun; 134(6):805-817. PubMed ID: 38599832
[TBL] [Abstract][Full Text] [Related]
29. CYP1A2 expression rather than genotype is associated with olanzapine concentration in psychiatric patients.
Fekete F; Menus Á; Tóth K; Kiss ÁF; Minus A; Sirok D; Belič A; Póti Á; Csukly G; Monostory K
Sci Rep; 2023 Oct; 13(1):18507. PubMed ID: 37898643
[TBL] [Abstract][Full Text] [Related]
30. Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration.
Citrome L; Stauffer VL; Chen L; Kinon BJ; Kurtz DL; Jacobson JG; Bergstrom RF
J Clin Psychopharmacol; 2009 Jun; 29(3):278-83. PubMed ID: 19440083
[TBL] [Abstract][Full Text] [Related]
31. Single- and multiple-dose pharmacokinetic, safety, and tolerability profiles of olanzapine long-acting injection: an open-label, multicenter, nonrandomized study in patients with schizophrenia.
Mitchell M; Kothare P; Bergstrom R; Zhao F; Jen KY; Walker D; Johnson J; McDonnell D
Clin Ther; 2013 Dec; 35(12):1890-908. PubMed ID: 24184052
[TBL] [Abstract][Full Text] [Related]
32. Impact of tobacco smoking cessation on stable clozapine or olanzapine treatment.
Lowe EJ; Ackman ML
Ann Pharmacother; 2010 Apr; 44(4):727-32. PubMed ID: 20233914
[TBL] [Abstract][Full Text] [Related]
33. Correlation between assessment of cytochrome P450 1A2 activity and enzyme activity scores, and their relation to clozapine exposure.
Alarcan H; Cannet P; Camus V; Fond G; Zendjidjian X; Guilhaumou R; Quaranta S
Br J Clin Pharmacol; 2023 May; 89(5):1665-1671. PubMed ID: 36507652
[TBL] [Abstract][Full Text] [Related]
34. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
Henderson DC; Cagliero E; Copeland PM; Borba CP; Evins AE; Hayden D; Weber MT; Anderson EJ; Allison DB; Daley TB; Schoenfeld D; Goff DC
Arch Gen Psychiatry; 2005 Jan; 62(1):19-28. PubMed ID: 15630069
[TBL] [Abstract][Full Text] [Related]
35. Influence of the genetic polymorphism in the 5'-noncoding region of the CYP1A2 gene on CYP1A2 phenotype and urinary mutagenicity in smokers.
Pavanello S; Pulliero A; Lupi S; Gregorio P; Clonfero E
Mutat Res; 2005 Nov; 587(1-2):59-66. PubMed ID: 16188490
[TBL] [Abstract][Full Text] [Related]
36. Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants.
Erickson-Ridout KK; Zhu J; Lazarus P
Pharmacogenet Genomics; 2011 Sep; 21(9):539-51. PubMed ID: 21750471
[TBL] [Abstract][Full Text] [Related]
37. Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison.
Kumra S; Kranzler H; Gerbino-Rosen G; Kester HM; De Thomas C; Kafantaris V; Correll CU; Kane JM
Biol Psychiatry; 2008 Mar; 63(5):524-9. PubMed ID: 17651705
[TBL] [Abstract][Full Text] [Related]
38. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine.
Carrillo JA; Herráiz AG; Ramos SI; Gervasini G; Vizcaíno S; Benítez J
J Clin Psychopharmacol; 2003 Apr; 23(2):119-27. PubMed ID: 12640212
[TBL] [Abstract][Full Text] [Related]
39. Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study.
Ujike H; Nomura A; Morita Y; Morio A; Okahisa Y; Kotaka T; Kodama M; Ishihara T; Kuroda S
J Clin Psychiatry; 2008 Sep; 69(9):1416-22. PubMed ID: 19193342
[TBL] [Abstract][Full Text] [Related]
40. Genetic variation in CYP3A43 explains racial difference in olanzapine clearance.
Bigos KL; Bies RR; Pollock BG; Lowy JJ; Zhang F; Weinberger DR
Mol Psychiatry; 2011 Jun; 16(6):620-5. PubMed ID: 21519338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
